https://www.avient.com/investor-center/news/polyone-announces-third-quarter-2019-results
Attachment 2
Tax adjustments(2)
2)
https://www.avient.com/investor-center/news/avient-announces-fourth-quarter-and-full-year-2024-results
Attachment 2
Tax adjustments(2)
2)
https://www.avient.com/investor-center/news/polyone-announces-third-quarter-2016-results
Attachment 2
Tax adjustments(2)
2) Tax adjustments include the net tax expense/benefit from one-time income tax items, the set-up or reversal of uncertain tax position reserves and deferred income tax valuation allowance adjustments.
https://www.avient.com/investor-center/news/polyone-announces-fourth-quarter-and-full-year-2019-results
Attachment 2
Tax adjustments(2)
2)
https://www.avient.com/investor-center/news/avient-announces-first-quarter-2024-results
Attachment 2
Tax adjustments(2)
2)
https://www.avient.com/investor-center/news/avient-announces-third-quarter-2020-results
Attachment 2
Tax adjustments(2)
2)
https://www.avient.com/investor-center/news/avient-announces-fourth-quarter-and-full-year-2022-results
Attachment 2
Tax adjustments(2)
2)
https://www.avient.com/news/polyone-announces-record-second-quarter-2015-results
Attachment 2
Tax adjustments(2)
2) Tax adjustments include the net tax expense/benefit from one-time income tax items and deferred income tax valuations allowance adjustments.
https://www.avient.com/sites/default/files/2022-05/MEVOPUR LQ for Silicone Elastomers_CN.pdf
在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。
https://www.avient.com/sites/default/files/2021-09/mevopur-colors-for-needle-hubs-bulletin-cn.pdf
在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。